Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Ionis Pharmaceuticals News

Aktie
WKN:  A2ACMZ ISIN:  US4622221004 US-Symbol:  IONS Branche:  Biotechnologie Land:  USA
64,14 €
+0,42 €
+0,66%
17.04.26
Depot/Watchlist
Marktkapitalisierung *
10,79 Mrd. €
Streubesitz
-
KGV
-47,75
Nachhaltigkeits-Score
52 %
Index-Zuordnung
Nasdaq Composite Index
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,81: MM5BB8
Werbung

Ionis Pharmaceuticals News

18.07.24 - PR Newswire
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire
25.06.24 - PR Newswire
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed PR Newswire
18.06.24 - PR Newswire
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema PR Newswire
17.06.24 - PR Newswire
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
Ionis to present at TD Cowen Genetic Medicines & RNA Summit PR Newswire
31.05.24 - PR Newswire
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema PR Newswire
28.05.24 - PR Newswire
Ionis to hold donidalorsen Phase 3 data webcast
Ionis to hold donidalorsen Phase 3 data webcast PR Newswire
23.05.24 - PR Newswire
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
New data from the Phase 3 NEURO-​TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) PR Newswire
16.05.24 - PR Newswire
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis PR Newswire
16.05.24 - PR Newswire
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome PR Newswire
15.05.24 - PR Newswire
Ionis to host 2024 virtual Annual Meeting of Stockholders
Ionis to host 2024 virtual Annual Meeting of Stockholders PR Newswire
25.04.24 - PR Newswire
Ionis Publishes 2023 Corporate Responsibility Report
Ionis Publishes 2023 Corporate Responsibility Report PR Newswire
23.04.24 - PR Newswire
Ionis to hold first quarter 2024 financial results webcast
Ionis to hold first quarter 2024 financial results webcast PR Newswire
07.04.24 - PR Newswire
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome PR Newswire
28.03.24 - PR Newswire
Ionis to hold olezarsen Phase 3 data webcast
Ionis to hold olezarsen Phase 3 data webcast PR Newswire
25.03.24 - PR Newswire
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting PR Newswire
13.03.24 - PR Newswire
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH PR Newswire
29.02.24 - PR Newswire
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Ionis announces new chief global product strategy officer to lead next phase of commercial growth PR Newswire
28.02.24 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
21.02.24 - PR Newswire
Ionis reports fourth quarter and full year 2023 financial results
Ionis reports fourth quarter and full year 2023 financial results PR Newswire
15.02.24 - PR Newswire
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »